Bone marrow aspirate concentrate was seen as a safe, reliable and viable cellular product for patients with bilateral knee pain from bilateral osteoarthritis, according to results.
Researchers randomly assigned 25 patients with bilateral knee pain from bilateral osteoarthritis (OA) to receive an intra-articular injection of bone marrow aspirate concentrate (BMAC) into one knee and saline placebo into the contralateral knee. Researchers tracked safety outcomes, pain relief and function measured by Osteoarthritis Research Society International measures and VAS score at 1 week, 3 months and 6 months postoperatively.
Shane A. Shapiro
From baseline to 1 week, 3months and 6 months postoperatively, results showed significant improvements in the intermittent and constant osteoarthritis pain score, intermittent pain score and total pain score among knees treated with either BMAC or saline. Researchers also noted significant improvements in VAS pain scores for both BMAC- and placebo-treated knees from baseline to 1 week, 3 months and 6 months postoperatively. Both treatments resulted in significant improvement in activity levels, according to results, with no difference in the degree of improvement at any of the follow-up periods. Researchers noted a decrease in use of over-the-counter or prescription pain medications from 100% at baseline to 24% at 3 months and 36% at 6 months. – by Casey Tingle
: Funding was received from the Center for Regenerative Medicine, Mayo Clinic. Please see the full study for a list of all other authors’ relevant financial disclosures.